Afamelanotide - Generic Drug Details

What are the generic sources for afamelanotide and what is the scope of patent protection?

Afamelanotide is the generic ingredient in one branded drug marketed by Clivunel Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Afamelanotide has twenty-three patent family members in sixteen countries.

There is one drug master file entry for afamelanotide. One supplier is listed for this compound.

Summary for afamelanotide

International Patents:	23
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	26
Clinical Trials:	23
What excipients (inactive ingredients) are in afamelanotide?	afamelanotide excipients list
DailyMed Link:	afamelanotide at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for afamelanotide

Constraining patent/regulatory exclusivity:

INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

Dosage:

IMPLANT;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for afamelanotide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Clinuvel Europe Limited	PHASE1
Clinuvel, Inc.	Phase 3
Clinuvel (UK) Ltd.	Phase 2

See all afamelanotide clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for afamelanotide

D02BB	Protectives against UV-radiation for systemic use
D02B	PROTECTIVES AGAINST UV-RADIATION
D02	EMOLLIENTS AND PROTECTIVES
D	Dermatologicals

US Patents and Regulatory Information for afamelanotide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes	8,334,265

Expired US Patents for afamelanotide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019	10,076,555

EU/EMA Drug Approvals for afamelanotide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Clinuvel Europe Limited	Scenesse	afamelanotide	EMEA/H/C/002548Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).	Authorised	no	no	yes	2014-12-22

International Patents for afamelanotide

Country	Patent Number	Title	Estimated Expiration
Canada	2662163
Denmark	2865422
South Africa	200901364	Method of treatment of photodermatoses
Portugal	2865422
European Patent Office	2056855	DÉRIVÉS DE LA MSH-ALPHA POUR LE TRAITEMENT DE PHOTODERMATOSES (ALPHA-MSH DERIVATIVES FOR THE TREATMENT OF PHOTODERMATOSES)
New Zealand	575133	METHOD OF TREATMENT OF PHOTODERMATOSES USING AN ALPHA-MSH ANALOGUE
Spain	2525476

Supplementary Protection Certificates for afamelanotide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2865422	CA 2018 00014	Denmark		PRODUCT NAME: AFAMELANOTIDE SAMT FARMACEUTISK ACCEPTABLE SALTE ELLER HYDRATER HERAF; REG. NO/DATE: EU/1/14/969 20141229
2865422	C201830012	Spain		PRODUCT NAME: AFAMELANOTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/14/969; DATE OF AUTHORISATION: 20141222; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/969; DATE OF FIRST AUTHORISATION IN EEA: 20141222
2865422	LUC00062	Luxembourg		PRODUCT NAME: AFAMELANOTIDE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (SCENESSE); AUTHORISATION NUMBER AND DATE: EU/1/14/969 20141229
2865422	18C1014	France		PRODUCT NAME: AFAMELANOTIDE; REGISTRATION NO/DATE: EU 1/14/969 20141229
2865422	2018/008	Ireland		PRODUCT NAME: AFAMELANOTIDE; REGISTRATION NO/DATE: EU/1/14/969 20141222
2865422	663	Finland
2865422	2018C/012	Belgium		PRODUCT NAME: AFAMELANOTIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/969 20141229

Afamelanotide: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is afamelanotide’s market position?

Afamelanotide is a melanocortin-1 receptor (MC1R) agonist administered as an implant for prevention of phototoxicity in erythropoietic protoporphyria (EPP). Commercial availability centers on Scenesse (afamelanotide) in EU markets and the UK, where it is used to reduce occurrence and severity of phototoxicity events in EPP patients. In the US, the commercial history is tied to regulatory and payer transitions rather than broad, durable scaling.

The market is structurally narrow:

• Indication concentration: EPP is rare and drives a limited addressable population.
• Administration format: the implant-based delivery constrains throughput and prescribing capacity relative to oral therapies.
• Specialist channel: dermatology/hematology networks dominate prescribing, which concentrates uptake decisions.

Where does demand come from, and what governs prescribing?

Demand for afamelanotide depends on four commercial levers.

1) Diagnosed patient pool and referral flow

EPP diagnosis and referral cadence drive new patient starts. The implant is typically deployed for patients with a clinically significant phototoxicity burden. This creates a “start-and-maintain” dynamic rather than high churn, with revenue patterns influenced by:

• survival and ongoing disease severity,
• patient adherence to scheduled implantation/seasonality,
• payer authorization practices in individual countries.

2) Phototoxicity event burden

Prescribers adopt afamelanotide when phototoxicity events have clinically meaningful frequency or severity. In practice, this means:

• patients with frequent summer UV exposure or work-related exposure are priority,
• switching from supportive care is more likely when events are recurrent.

3) Health-technology assessment (HTA) and payer constraints

European uptake is determined by country-level reimbursement outcomes and pricing negotiations. HTA bodies typically assess:

• clinical benefit in reducing phototoxicity events,
• quality-of-life impact,
• cost-effectiveness given rare disease prevalence.

4) Competitive alternatives for EPP

The competitive set in EPP is limited. Market share is mainly driven by comparative outcomes and access rather than head-to-head blockbuster competition. Where supportive care and intermittent interventions remain options, payer criteria can slow conversion to afamelanotide.

What pricing and reimbursement realities shape the financial trajectory?

Across rare disease markets, pricing and payer acceptance usually follow a repeatable path: launch price is negotiated for the first wave of coverage, and then revenues track reimbursement stability and the ability to expand access country-by-country.

For afamelanotide specifically, the financial trajectory has been shaped by:

• European launch and reimbursement sequencing (coverage expands by country, not instantly across regions),
• tender and budget impact reviews in health systems,
• patient access variability due to authorization requirements for implant therapies.

How has the revenue trajectory evolved since launch?

Financial outcomes for afamelanotide are reported primarily through company disclosures, rare-disease commercial updates, and country-level reimbursement milestones. Public reporting is fragmented because the drug is not widely cited in mainstream quarterly earnings the way larger franchises are.

In business terms, the trajectory follows three phases:

1. Launch and coverage build (reimbursement expansion)
   Revenue growth follows new country approvals and favorable payer decisions.
2. Stabilization (patient pool maturation)
   Growth becomes less about new prescribers and more about retention, re-implant schedules, and predictable seasonal utilization.
3. Reacceleration only with access expansion or label-driven growth
   Without new indications or major reimbursement changes, growth is capped by the diagnosed EPP population.

What market risks and catalysts could change growth?

Catalysts that tend to move afamelanotide economics

• Reimbursement wins or expanded criteria that increase eligible patient numbers
• New country access in Europe and comparable systems
• Clinical evidence uptake that supports broader use among higher-burden EPP patients

Risks that tend to compress or delay financial results

• Tight payer criteria that limit eligible starts to a narrow severity band
• Budget impact scrutiny that slows country-by-country coverage expansion
• Competitive substitution where clinicians or payers favor alternative management approaches
• Supply chain and implant logistics that can constrain availability at start of coverage expansion

What competitive dynamics matter in a rare disease market?

Afamelanotide faces competition in EPP primarily through treatment alternatives that aim to reduce phototoxicity events, as opposed to the “growth” dynamics seen in common diseases. That changes the competitive model:

• Rather than shelf-share, competition is about payer acceptance and clinical positioning (benefit-risk in phototoxicity reduction).
• In rare diseases, even small changes in access criteria can materially impact the number of treatable patients, so market share shifts occur less through aggressive marketing and more through reimbursement mechanics.

What regulatory and lifecycle factors shape the market?

Afamelanotide’s core market is tied to its indication and regulatory labeling. Lifecycle events that matter commercially:

• label updates that expand patient eligibility,
• additional evidence that strengthens HTA cost-effectiveness,
• manufacturing or delivery improvements that reduce access friction.

How does afamelanotide’s financial model compare to typical rare disease commercial patterns?

Afamelanotide aligns with rare disease norms:

• Revenue is not driven by massive unit volume; it is driven by a small but relatively persistent patient base.
• Forecasting depends on coverage mapping (country access and criteria), not on broad population growth.
• Growth inflection requires coverage expansion or additional indications. Absent that, the financial ceiling is set by diagnosed prevalence and payer entry barriers.

What does the market imply for investors or R&D planners?

For investment-grade analysis, the key question is not whether patients exist, but whether:

• payers will cover afamelanotide at scale within EPP,
• clinicians can access implant delivery without delays,
• the total addressable and reimbursed population continues expanding.

The market remains relatively insulated from “macro” demand drivers because it is rare disease-driven and clinic-referral-driven.

---

Key Takeaways

• Afamelanotide’s market is structurally narrow because it is concentrated in EPP, with demand governed by diagnosis and payer criteria.
• Revenue trajectory typically follows a rare-disease pattern: coverage expansion first, then stabilization as the patient pool matures.
• The principal financial levers are reimbursement breadth, authorization ease, and continued retention of implanted patients.
• Without additional indications or major access expansions, growth remains capped by reimbursed eligible population and country-level HTA outcomes.

---

FAQs

1. What is afamelanotide used for commercially?
   Prevention of phototoxicity in patients with erythropoietic protoporphyria (EPP) under the Scenesse product label in covered jurisdictions.

2. What drives unit consumption in EPP?
   The implant dosing and scheduled re-implantation patterns tied to clinical phototoxicity burden and ongoing specialist care.

3. Why is afamelanotide’s market growth limited versus common-disease drugs?
   EPP is rare, and pricing and access are constrained by HTA and payer authorization for eligible patients.

4. What tends to change the revenue outlook fastest?
   Country-by-country reimbursement wins, expanded eligibility criteria, and label or evidence changes that strengthen cost-effectiveness and clinical positioning.

5. How do competitive dynamics play out in EPP?
   Competition centers on reimbursement and treatment choice for reducing phototoxicity events, not on large-scale switching across mass-market prescribers.

---

References

[1] European Medicines Agency. Scenesse (afamelanotide): EPAR product information. European Union. https://www.ema.europa.eu/ (accessed via Scenesse EPAR page).